Today: 30 June 2026
Snowflake stock slides after Barclays downgrade, putting SNOW’s valuation debate back in play
14 January 2026
1 min read

Snowflake stock slides after Barclays downgrade, putting SNOW’s valuation debate back in play

NEW YORK, Jan 14, 2026, 05:28 EST — Premarket

Snowflake Inc shares hovered near $209 in premarket trade on Wednesday after ending Tuesday down 4.94% at $209.39, as a Barclays downgrade pushed investors back to an old worry: how much upside is left at this price. The pullback came alongside a broader retreat in tech shares.

The downgrade matters now because Snowflake has become a kind of temperature check for high-growth cloud software. When a big bank goes neutral, it can spill into the whole group, even if nothing at the company changed overnight.

It also lands early in the year, when money tends to move fast between “growth at any price” and “show me the numbers.” Snowflake’s business is tied to customer usage, and that keeps traders jumpy.

Barclays analyst Raimo Lenschow cut Snowflake to Equal-Weight from Overweight and lowered his price target to $250 from $290, GuruFocus reported. In brokerage terms, an “overweight” rating is a call to beat peers, while “equal weight” signals a more neutral stance. GuruFocus

Lenschow said he still sees Snowflake as a “best-in-class software asset,” but warned of “limited upside going forward” after the stock’s outperformance, according to Seeking Alpha. Barclays also cut ratings on GitLab and DoubleVerify while upgrading Descartes Systems in its 2026 software outlook, the report said. Seeking Alpha

In Tuesday’s session, Snowflake traded as low as $207.50 and last changed hands around $209, with about 8 million shares traded, MarketBeat reported. The stock had previously closed at $220.28, the site said.

The move played out against a softer day on Wall Street, where U.S. stocks ended lower on Tuesday led by financials after JPMorgan executives flagged risks tied to a proposed cap on credit-card rates, Reuters reported. The S&P 500 slipped 0.19% and the Nasdaq fell 0.10%, the report said.

Snowflake sells cloud software that helps companies store and analyze data. A large chunk of its revenue is tied to how much customers use the platform, which can swing with IT budgets and new projects.

The risk for bulls is simple: if customers keep trimming cloud spend, or if competition for new workloads stays intense, the stock can struggle to regain its footing. When a name is priced for strong growth, small cracks can look big.

Next up is earnings. Snowflake is expected to report on Feb. 25, according to Public.com, and that date is likely to be the next clear catalyst for SNOW shares.

Investors will be listening for any change in the pace of usage growth and the tone around new product demand. After this week’s downgrade, the bar for “good enough” may have moved.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Theravance Biopharma (TBPH) Slides 3% After $929M Zymeworks (ZYME) Deal Announced
    June 30, 2026, 10:24 AM EDT. Theravance Biopharma (TBPH) shares slipped about 3% on June 29, 2026, after Zymeworks (ZYME) said it would buy the company in an all-cash deal valued at around $929 million. The deal is set to close in H2 2026. Theravance went up for sale after its main drug, ampreloxetine, missed in Phase III trials. Most of Theravance's revenue came from a single COPD collaboration. The buyout gives shareholders $17 per share, which is a 22% premium to the March 3 close, plus CVRs linked to future ampreloxetine proceeds. Management called the move the best route for shareholder value as operational cuts and slow growth continue. Theravance has a Zacks Rank #4 (Sell).
Locked out of $22B: Canadian real estate funds freeze withdrawals as gates spread
Previous Story

Locked out of $22B: Canadian real estate funds freeze withdrawals as gates spread

Kohl’s stock slides 5% as Jefferies trims target to $22, tariff ruling keeps retailers on edge
Next Story

Kohl’s stock slides 5% as Jefferies trims target to $22, tariff ruling keeps retailers on edge

Go toTop